Photo by matteo_skyrider from unsplash
Difucosyllactose (Di‐FL) has strong antimicrobial activity against various pathogens, including group B Streptococcus, identified as the leading cause of neonatal sepsis. In this study, we sought to develop Escherichia coli… Click to show full abstract
Difucosyllactose (Di‐FL) has strong antimicrobial activity against various pathogens, including group B Streptococcus, identified as the leading cause of neonatal sepsis. In this study, we sought to develop Escherichia coli as a microbial cell factory for efficiently producing Di‐FL as well as 2′‐fucosyllactose (2′‐FL), the most abundant fucosylated oligosaccharide in human milk, by utilizing the salvage guanosine 5′‐diphosphate (GDP)‐l‐fucose biosynthetic pathway.
Keywords:
fucosyllactose difucosyllactose;
difucosyllactose engineered;
escherichia coli;
simultaneous production;
engineered escherichia;
production fucosyllactose
Journal Title: Biotechnology Journal
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Biotechnology Journal
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!